Literature DB >> 15673770

AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii.

Alexey Ruzin1, David Keeney, Patricia A Bradford.   

Abstract

Transposon mutagenesis of a clinical isolate of Morganella morganii, G1492 (tigecycline MIC of 4 microg/ml), yielded two insertion knockout mutants for which tigecycline MICs were 0.03 microg/ml. Transposon insertions mapped to acrA, which is constitutively overexpressed in G1492, suggesting a role of the AcrAB efflux pump in decreased susceptibility to tigecycline in M. morganii.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15673770      PMCID： PMC547285          DOI： 10.1128/AAC.49.2.791-793.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

Authors:  H W Boucher; C B Wennersten; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

2.  Increase in MICs of ciprofloxacin in vivo in two closely related clinical isolates of Enterobacter cloacae.

Authors:  Hans-Jörg Linde; Frank Notka; Christine Irtenkauf; Jochen Decker; Jens Wild; Hans-Helmut Niller; Peter Heisig; Norbert Lehn
Journal:  J Antimicrob Chemother       Date:  2002-04       Impact factor: 5.790

3.  Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae.

Authors:  Alexey Ruzin; Melissa A Visalli; David Keeney; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Small broad-host-range gentamycin resistance gene cassettes for site-specific insertion and deletion mutagenesis.

Authors:  H D Schweizer
Journal:  Biotechniques       Date:  1993-11       Impact factor: 1.993

5.  mar Operon involved in multidrug resistance of Enterobacter aerogenes.

Authors:  Renaud Chollet; Claude Bollet; Jacqueline Chevalier; Monique Malléa; Jean-Marie Pagès; Anne Davin-Regli
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

6.  Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

Authors:  Charles R Dean; Melissa A Visalli; Steven J Projan; Phaik-Eng Sum; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

Review 7.  New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors.

Authors:  Ian Chopra
Journal:  Drug Resist Updat       Date:  2002 Jul-Aug       Impact factor: 18.500

8.  In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.

Authors:  Peter J Petersen; Patricia A Bradford; William J Weiss; Timothy M Murphy; P E Sum; Steven J Projan
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Role of AcrR and ramA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore.

Authors:  T Schneiders; S G B Amyes; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli.

Authors:  M Oethinger; I Podglajen; W V Kern; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191
View more
  24 in total

Review 1.  Tigecycline.

Authors:  James E Frampton; Monique P Curran
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria.

Authors:  Laura J V Piddock
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

3.  Functional, biophysical, and structural bases for antibacterial activity of tigecycline.

Authors:  Matthew W Olson; Alexey Ruzin; Eric Feyfant; Thomas S Rush; John O'Connell; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  ramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecycline.

Authors:  M Hentschke; M Wolters; I Sobottka; H Rohde; M Aepfelbacher
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

Review 5.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 6.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 7.  Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?

Authors:  Alejandro Beceiro; María Tomás; Germán Bou
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

8.  Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae.

Authors:  Charles R Dean; David T Barkan; Alun Bermingham; Johanne Blais; Fergal Casey; Anthony Casarez; Richard Colvin; John Fuller; Adriana K Jones; Cindy Li; Sara Lopez; Louis E Metzger; Mina Mostafavi; Ramadevi Prathapam; Dita Rasper; Folkert Reck; Alexey Ruzin; Jacob Shaul; Xiaoyu Shen; Robert L Simmons; Peter Skewes-Cox; Kenneth T Takeoka; Pramila Tamrakar; Tsuyoshi Uehara; Jun-Rong Wei
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

9.  [Septic shock due to vancomycin-resistant enterococci infection. Tigecycline monotherapy].

Authors:  S Swoboda; T Hoppe-Tichy; H K Geiss; C Hainer; T H Nguyen; H-P Knaebel; M A Weigand
Journal:  Anaesthesist       Date:  2007-02       Impact factor: 1.041

Review 10.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.